Antibe Therapeutics Inc. (USD) Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.

Antibe Therapeutics Inc. (USD) Passive

15 Prince Arthur Avenue, Toronto, ON, CA, M5R 1B2

Stock Price USD

Price Change

Last Dividend USD

ATBPF's stock peer is CDXFF (Cloud DX Inc.)

ATBPF's stock peer is CNPOF (RIV Capital Inc.)

ATBPF's stock peer is EIGRQ (Eiger BioPharmaceuticals, Inc.)

ATBPF's stock peer is LVCLY (Living Cell Technologies Limited)

ATBPF's stock peer is LXXGF (LexaGene Holdings Inc.)

ATBPF's stock peer is MGCLF (MGC Pharmaceuticals Limited)

ATBPF's stock peer is MRVFF (Nuvo Pharmaceuticals Inc.)

ATBPF's stock peer is RXMD (Progressive Care, Inc.)

ATBPF's stock peer is TMDIF (Titan Medical Inc.)

ATBPF's stock peer is VRCDF (Verici Dx plc)

Healthcare Medical - Devices

Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions